Who are Miromatrix's investors?

Miromatrix's investors include Brightstone Venture Capital.

How much funding has Miromatrix raised?

Miromatrix has disclosed $39.5M raised across 2 rounds.

Where is Miromatrix headquartered?

Miromatrix is headquartered in Eden Prairie, US.

Miromatrix

Eden Prairie, US · 1 known investors

Miromatrix develops bioengineered human organs using a proprietary perfusion decellularization and recellularization technology, in which cells are removed from a pig organ and human cells are introduced into the resulting matrix. The company aims to create fully transplantable human organs to address the shortage of donor organs for transplant patients in the U.S.

Biotech Longevity Medical Devices

Founders & leadership

Jeff RossExecutive

Robert CohenNamed on SEC filing

Joseph AlexanderSecretary

Board

Ronald EibensteinerBoard director

Timothy FlynnBoard director

Walter SembrowichBoard director

Timothy J. PawlentyBoard director

Investors · 1

Brightstone Venture CapitalMinneapolis · $250K – $10M

Reported raises · per SEC filings

Form D private placements

$39.5M disclosed across 2 rounds · 2013–2017

▶$15.7MraisedJul 2018 · 55 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ronald EibensteinerDirector
Mark WagnerDirector
Paul BuckmanDirector
Jeffrey RossExecutive Officer, Director
John J. ErbDirector
Brian NieburExecutive Officer

Offering amount: $15.7M
Amount sold: $15.7M
First sale: Oct 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$23.8MraisedNov 2015 · 124 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Timothy FlynnDirector
Robert CohenExecutive Officer, Director, Promoter
Joseph AlexanderExecutive Officer
Jeff RossExecutive Officer
Ronald EibensteinerDirector
Walter SembrowichDirector
Timothy J. PawlentyDirector

Offering amount: $25M
Amount sold: $23.8M
Minimum investment: $50K
Finders' fees: $171.3K
Placement agents: Van Clemens & Co., Inc., Terence J. Redmond, Woodrow L. Blevins, Mark D. Witmer, Blake Capital Partners, LLC, Valenti Synergy Consulting, LLC, Charlie Nickoloff
First sale: Oct 2013
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Mirum Pharmaceuticals14 shared keywordsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.

Bioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Mereo BioPharma Group9 shared keywordsMereo BioPharma is a biopharmaceutical company that develops novel therapies for rare diseases with limited or no treatment options, focusing on lead programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). It operates a capital-efficient model, acquiring high-potential therapies from pharmaceutical and biotechnology companies and advancing them through clinical development in partnership with patient communities.

Epirium9 shared keywordsEpirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.

Companies competing with Miromatrix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Miromatrix do?: Miromatrix develops bioengineered human organs using a proprietary perfusion decellularization and recellularization technology, in which cells are removed from a pig organ and human cells are introduced into the resulting matrix. The company aims to create fully transplantable human organs to address the shortage of donor organs for transplant patients in the U.S.
Who are Miromatrix's investors?: Miromatrix's investors include Brightstone Venture Capital.
How much funding has Miromatrix raised?: Miromatrix has disclosed $39.5M raised across 2 rounds.
Where is Miromatrix headquartered?: Miromatrix is headquartered in Eden Prairie, US.